Taken together, we identified and validated GNAS KO as a sensitizer to HDAC3 inhibition based on results of distinct sgRNAs and multiple HDAC3-targeting compounds in both human and mouse lymphoma cell lines, showing a consistent and conserved phenotype. Here, HDAC3 is linked to lymphoma.